MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Northwestern University Adopts Y90 TARE with TheraSphere® as First-line Treatment for HCC - Based on experience with 1000 patients over 15 years, the largest single-centre prospective, cohort of patients with HCC treated with Y90 glass microspheres - therasphere.com / BTG-IM.com
Northwestern University Adopts Y90 TARE with TheraSphere® as First-line Treatment for HCC

 

NewswireToday - /newswire/ - London, United Kingdom, 2017/12/12 - Based on experience with 1000 patients over 15 years, the largest single-centre prospective, cohort of patients with HCC treated with Y90 glass microspheres - therasphere.com / BTG-IM.com. LSE: BTG

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BTG plc, a global specialist healthcare company, today announced that following positive results of its 15-year experience between 2003 and 2017 with TheraSphere®, Northwestern University, Illinois has adopted Y90 transarterial radioembolisation (TARE) with TheraSphere® as the primary trans-arterial loco-regional therapy (LRT) for patients with hepatocellular carcinoma (HCC) limited to the liver.1

HCC is considered to be the most common primary liver cancer and represents the second most common cause of cancer mortality worldwide.2 Northwestern University’s decision to adopt TARE with TheraSphere® as a first-line transarterial LRT for patients with HCC was informed by data prospectively collected and incrementally reported, demonstrating outcomes as expected by the BCLC algorithm for stages A-D, applied as either neoadjuvant or definitive treatment. Compared with TACE, the data confirm that outpatient TARE allows for fewer treatments, better quality of life, longer time to progression and versatile application as neoadjuvant LRT combined with either resection or orthotopic liver transplantation.1

“Patients are looking for treatments that are safe, efficacious, have minimal detrimental effects on their quality of life and as pain free as possible,” said Dr Riad Salem, Chief, Section of Vascular & Interventional Radiology, Department of Radiology at Northwestern University and lead author of the paper ‘“Institutional Decision to Adopt Y90 as Primary Treatment for HCC Informed by a 1,000-patient 15-year Experience” recently accepted for publication in Hepatology.1

“The benefit of Y90 TARE with TheraSphere® is that it meets all of these patient needs, and also enables patients to be treated as outpatients, permitting discharge on the same day, reducing the need for lengthy hospitalisations and minimising impact on daily life. We recognise the many approaches to establishing a new standard of care. In our case, we are proud of the controlled, prospective studies we completed over the last decade, each addressing a specific question, and each getting us closer to the unanimous, multidisciplinary adoption of Y90 as first-line. We are hopeful that when colleagues and peers review the study, the long-term survival outcomes, our rationale and the strength of the evidence, many will follow suit.”

Peter Pattison, BTG General Manager Interventional Oncology, commented,“We are delighted that Northwestern University Hospital has chosen to adopt Y90 TARE with TheraSphere® as the first line trans-arterial LRT for patients with HCC. This first publication featuring over 1000 HCC patients treated with TheraSphere® represents a major milestone and we are proud to partner with healthcare professionals to deliver improved treatment options for patients.”

Since TARE Y90 was FDA approved in 1999 and made available for clinical use in early 2000, radiation therapy has become widely available as an effective option to treat HCC.2 Treatment with Y90 TARE infuses TheraSphere® Y90 glass microspheres into the arteries that feed liver tumours. The microspheres deliver a targeted radiation dose to the tumour, minimising exposure to healthy tissue and can be adapted for each patient, allowing for a personalised treatment approach.

About BTG Interventional Oncology
BTG Interventional Oncology (btg-im.com) is transforming the way cancer is treated with wide-ranging solutions consisting of minimally-invasive, highly targeted therapies that can be personalised to each patient’s needs. Our products are used to treat or provide symptomatic relief for people with cancer and benign tumors.

About TheraSphere®
TheraSphere® Y90 glass microspheres (therasphere.com) are specifically engineered to carry far greater power than any other Y90 liver-directed cancer therapy, delivering high doses of radiation to liver tumours while sparing normal tissue. The result is a powerful, targeted and well-tolerated therapy that may lead to patients becoming eligible for curative therapies. In the EU, Singapore, South Korea and Canada, TheraSphere® is approved for the treatment of hepatic neoplasia. In the US, TheraSphere® is approved under a Humanitarian Device Exemption (HDE) for use in radiation treatment or as a neoadjuvant to surgery or transplantation in patients with unresectable hepatocellular carcinoma (HCC) who can have placement of appropriately positioned hepatic arterial catheters. The device is also indicated for HCC patients with partial or branch portal vein thrombosis/occlusion, when clinical evaluation warrants the treatment. The effectiveness of this device for this use has not been demonstrated.

Media Liaison Contact: Director Jonathan Falcone
M: +44(0)78 2523 8898

References:
1. Salem R et al. Hepatology 2017; Accepted for publication.
2. Tanguturi S K et al. The Oncologist 2014.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Northwestern University Adopts Y90 TARE with TheraSphere® as First-line Treatment for HCC

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Chris Sampson - BTGplc.com 
+44(0)20 7575 1595 / +44(0)77 7325 1178 (mobile) chris.sampson[.]btgplc.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biocompatibles UK Ltd / BTG Plc securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Biocompatibles UK Ltd / BTG Plc / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Huntington Study Group Ltd





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)